Personalis, Inc.
Personalis, Inc. (NASDAQ: PSNL) is an advanced cancer genomic testing company that develops, markets, and sells precision oncology diagnostic services. The company operates a CLIA-certified and CAP-accredited clinical laboratory located in Fremont, California, where it performs comprehensive genomic sequencing and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Personalis, Inc. does
In the company’s own words
Personalis, Inc. (NASDAQ: PSNL) is an advanced cancer genomic testing company that develops, markets, and sells precision oncology diagnostic services. The company operates a CLIA-certified and CAP-accredited clinical laboratory located in Fremont, California, where it performs comprehensive genomic sequencing and analysis for cancer patients, pharmaceutical companies, and diagnostic organizations.
The company's primary testing services include NeXT Personal Dx, an ultrasensitive tumor-informed liquid biopsy test for detecting minimal residual disease and monitoring cancer recurrence in solid tumors, and NeXT Dx, a comprehensive tumor profiling test designed to identify actionable mutations and potential clinical trials for cancer patients. For pharmaceutical and biopharmaceutical customers, Personalis offers NeXT Personal for clinical trial applications and ImmunoID NeXT, a tissue-based test combining whole exome and transcriptome sequencing to analyze tumor microenvironments and identify neoantigens for personalized cancer therapies. The company also provides whole exome sequencing and whole genome sequencing services for diagnostic companies and population sequencing initiatives.
Personalis generates revenue primarily from the United States, which accounted for 90 percent of total revenue in 2025, with Europe representing 9 percent and other regions comprising 1 percent. The company's customer base includes global pharmaceutical companies, biopharmaceutical firms, diagnostics companies, academic institutions, government entities, and cancer patients. Key customers include Moderna and the U.S. Department of Veterans Affairs' Million Veteran Program, which collectively represented significant portions of revenue. The company distributes its services through a direct sales force organized by geography and maintains a commercialization partnership with Tempus AI for co-marketing NeXT Personal Dx in clinical diagnostics and biopharma markets.
Personalis operates as a single business segment focused on providing advanced cancer genomic testing services for precision oncology applications. The company's competitive advantages include its ultrasensitive technology platform capable of detecting cancer recurrence earlier than competing approaches, comprehensive data analysis capabilities, and established relationships with leading cancer centers and academic research institutions. The company's intellectual property portfolio includes 36 issued U.S. patents and 26 issued foreign patents covering personalized genetic testing assays, liquid biopsy methods, and related technologies, with patents expected to expire between 2033 and 2045.
Company details
- Sector
- Healthcare
- Industry
- Health Services
- Headquarters
- FREMONT, CA
- Fiscal year end
- December
- CIK
- 1527753
- SIC
- 8071
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Personalis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Personalis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Personalis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Personalis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Personalis, Inc.'s last four quarterly filings that the numbers alone won't show?”